Moderna Inc. ($MRNA) Stock Forecast: Down 7.0% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company renowned for its groundbreaking mRNA technology, particularly in the field of vaccine development. The company has gained attention for its efforts in combatting various diseases, including COVID-19.

Why is Moderna Inc. going down?

MRNA stock is down 7.0% on Feb 3, 2026 18:46

• Despite a positive performance over the past year and year-to-date, Moderna's stock witnessed a bearish movement today. This comes in light of successful partnerships and promising experimental vaccines.
• The robust financial results and pipeline progress of Merck & Co. may have diverted investor attention from Moderna, impacting MRNA's stock adversely.
• Moderna's announcement of an upcoming webinar on decision intelligence for an autonomous cold chain underscores its dedication to innovation. However, this development might not have been sufficient to counter the prevailing market sentiment affecting MRNA's stock.
• The FDA's recent request for monitoring myocarditis in a new COVID antibody trial possibly added to market uncertainty. This factor could have influenced the bearish movement in Moderna's stock observed today.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Are Wall Street Analysts Bullish on Moderna Stock?

Moderna (MRNA) has outperformed the S&P 500 over the past year and year-to-date, driven partly by positive results from its experimental skin cancer vaccine partnership with Merck. Despite a "Hold" consensus rating from analysts, some maintain a "Buy" rating with significant potential upside. The company's earnings surprise history is positive, with analysts expecting a narrowing loss per share for the current fiscal year.

https://www.palmettograin.com/news/story/37385520/are-wall-street-analysts-bullish-on-moderna-stock

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

Merck & Co. announced strong financial results for the fourth quarter and full year 2025, driven by oncology and animal health, and increasing contributions from new products like WINREVAIR and CAPVAXIVE. The company reported fourth-quarter worldwide sales of $16.4 billion and full-year sales of $65.0 billion, demonstrating progress in its diverse pipeline and strategic acquisitions. Merck also provided a full-year 2026 financial outlook, anticipating worldwide sales between $65.5 billion and $67.0 billion.

https://www.pharmiweb.com/press-release/2026-02-03/merck-co-inc-rahway-nj-usa-announces-fourth-quarter-and-full-year-2025-financial-results

How Moderna Uses Decision Intelligence to Enable an Autonomous Cold Chain, Upcoming Webinar Hosted by Xtalks

Moderna is transforming its cold chain logistics using decision intelligence to create an autonomous system that reduces waste, cuts costs, and minimizes manual intervention. A webinar hosted by Xtalks will detail how Moderna is achieving this by focusing on visibility beyond tracking, consolidating data, and integrating planning, operations, and quality workflows. This phased approach aims for a "hands-free" supply chain, leveraging trusted performance data to drive faster product release and smarter network design.

https://ca.finance.yahoo.com/news/moderna-uses-decision-intelligence-enable-133000814.html

Outpatient Oncology Infusion Market to Reach USD 7.0 Billion

The outpatient oncology infusion market is projected to reach USD 7.0 billion by 2035, growing at a CAGR of 10.4% from 2025. This growth is driven by advancements in cancer therapies, increasing cancer prevalence, and a shift towards outpatient care. North America currently leads the market, while Asia Pacific is expected to be the fastest-growing region, with key players like InfuSystem, Baxter, and Becton Dickinson supporting innovation in this sector.

https://www.openpr.com/news/4375527/outpatient-oncology-infusion-market-to-reach-usd-7-0-billion

FDA asks Invivyd to track myocarditis in new COVID antibody vs vaccine trial

Invivyd (Nasdaq: IVVD) has aligned with the FDA on the LIBERTY Phase 3 clinical trial, which will evaluate the safety and immunologic profile of its VYD2311 antibody against mRNA COVID vaccines and also study co-administration. The FDA specifically requested monitoring for myocarditis/pericarditis due to known risks associated with mRNA vaccines. This trial aims to offer an exploratory comparison to the DECLARATION trial, with topline data for DECLARATION expected mid-2026.

https://www.stocktitan.net/news/IVVD/invivyd-aligns-with-the-u-s-fda-on-liberty-a-phase-3-trial-to-zloa4zwf3ox4.html

Trending Today

Jupiter ($JUP) Crypto Forecast: Down 5.1% Today

Silver ($XAG) Commodity Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Down 6.0% Today

Cosmos ($ATOM) Crypto Forecast: Up 5.1% Today

Gold ($XAU) Commodity Forecast: Up 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 5.2% Today

Revvity ($RVTY) Stock Forecast: Down 5.3% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.1% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 5.1% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Down 6.1% Today

Moderna Inc. Price History

30.00.2026 - MRNA Stock was down 5.4%

• A recent partnership for the development of mRNA-3927 for propionic acidemia highlights Moderna's dedication to broadening its portfolio beyond vaccines.
• The appointment of Dr. David Berman as Chief Development Officer brings valuable expertise in immunotherapy, potentially indicating a shift towards advancing clinical-stage therapies.
• Despite recent positive developments, concerns over financial pressures and an ambitious profitability target set for 2028 have led to a bearish market reaction.
• Investors may be cautious about the leadership transition from Dr. Jacqueline Miller to Dr. David Berman, as such changes can introduce uncertainties impacting stock performance.

30.00.2026 - MRNA Stock was down 5.7%

• Moderna's stock experienced a bearish movement following the announcement of the departure of its chief medical officer amidst other executive departures within the company.
• The appointment of Dr. David Berman as the new Chief Development Officer was not enough to offset the negative sentiment, as investors may be concerned about the leadership changes and potential impact on the company's future direction.
• The partnership with Recordati to develop an mRNA therapy for a rare metabolic disorder was a positive development, but it seems the market focused more on the internal leadership changes at Moderna.
• The overall market reaction suggests that investors are closely monitoring Moderna's executive team transitions and the company's ability to maintain its innovative edge in mRNA technology amidst leadership shake-ups.

27.00.2026 - MRNA Stock was up 6.0%

• MRNA stock experienced a bullish movement today.
• The positive market sentiment towards MRNA could be attributed to recent advancements in personalized cancer vaccines by another company, potentially boosting confidence in the biotech sector.
• Additionally, positive developments in the biotech industry, such as progress with a therapy for bladder cancer by another company, may have created a ripple effect of optimism among investors, benefiting companies like MRNA.
• Overall, the growing interest and potential breakthroughs in the biotech field seem to have contributed to the bullish movement in MRNA stock today.

27.00.2026 - MRNA Stock was down 5.2%

• Moderna (MRNA) underwent a period of bearish movement, potentially influenced by positive developments and growth projections of major competitors in the oncology market, including Merck (MRK), Oncolytics Biotech Inc. (ONCY), and other industry participants.
• Merck's (MRK) anticipated rise in earnings and revenues, progress in its oncology pipeline, and revised growth forecasts might have redirected investor attention from Moderna, leading to a decline in its stock performance.
• Analysts' call for enhanced clarity on long-term growth prospects at Merck, despite its notable performance, may have prompted investor apprehensions regarding Moderna's competitiveness and future growth trajectory in biotechnology.
• References to AI stocks presenting superior upside potential compared to Merck could have shifted investor focus towards alternative investment options, thereby contributing to the downward trend in Moderna's stock value.

23.00.2026 - MRNA Stock was down 10.9%

• The stock's decline may have been driven by profit-taking by investors following a recent 4% rally linked to positive five-year follow-up data for their mRNA cancer vaccine in collaboration with Merck.
• Concerns about potential competition or market positioning for Moderna in the oncology sector could have arisen with the amendment of the license agreement between Terns Pharmaceuticals and Hansoh for TERN-701 rights.
• Investor focus and capital might have been redirected towards the banking sector, particularly awaiting Itaú Unibanco's Q4 results, contributing to Moderna's downward trend.
• Despite the promising long-term prospects in oncology, external factors and short-term market dynamics possibly influenced the bearish performance today.

23.00.2026 - MRNA Stock was down 9.4%

• Moderna's stock saw a strong bearish movement possibly due to the announcement of limiting investment in new late-stage vaccine trials, reflecting concerns over achieving returns amidst regulatory hurdles and opposition in the US market.
• The groundbreaking five-year follow-up data for their mRNA cancer vaccine, which demonstrated positive results in high-risk melanoma patients, might have been overshadowed by the decision to curb vaccine trial investments, leading to investor uncertainty.
• The amended license agreement with Hansoh for TERN-701 by Terns Pharmaceuticals could have also impacted Moderna's stock negatively, as it potentially shifts focus and resources away from certain therapeutic products.
• Overall, the market may be reacting to the shifting priorities and strategies within Moderna, as it navigates challenges in the regulatory landscape and transitions towards personalized cancer treatments, impacting investor sentiment and stock performance.

23.00.2026 - MRNA Stock was down 10.7%

• The stock's decline could be attributed to profit-taking or concerns about vaccine distribution challenges.
• Positive updates on Lucid Group, Materion Corp, and Terns Pharmaceuticals might have shifted investor focus away from Moderna.
• Other companies' positive news and Itaú Unibanco's upcoming investor meeting could have added to the downward pressure on Moderna's stock.
• Despite today's bearish movement, Moderna's long-term outlook remains optimistic due to its crucial role in the pandemic response and continuous vaccine innovations.

28.00.2026 - MRNA Stock was down 8.4%

• An analyst initiated coverage on Moderna with an "equal weight" rating and a $25.00 price target, indicating a significant downside potential from its current price. This negative sentiment from analysts likely contributed to the bearish movement.
• The weak fundamentals of Moderna, such as negative EPS and revenue declines, could have further fueled investor concerns and led to the sell-off.
• The lack of growth in revenue and poor financial outlook for biotech companies like BioNTech SE, may have cast a shadow on Moderna's prospects, impacting its stock performance.
• Overall, the combination of negative analyst ratings, weak financial fundamentals, and broader industry concerns about revenue growth in the biotech sector likely contributed to Moderna's bearish market movement today.

02.01.2026 - MRNA Stock was up 5.3%

• Moderna's upward momentum can be associated with the encouraging insights shared during the 44th Annual J.P. Morgan Healthcare Conference. The company emphasized its strategic business expansion, progress in product development, and anticipated financial performance over the upcoming years.
• The market responded positively to Moderna's detailed three-year business plan revealed during its Analyst Day. The plan included forecasts for revenue growth, expansion of its vaccine portfolio, and a heightened focus on oncology and rare disease treatments.
• Investors seemingly responded to Moderna's growth potential, despite concerns raised regarding declining revenue and projected performance compared to industry standards. The optimistic narrative presented by Moderna during recent conferences likely overshadowed these underlying challenges in the near term.

03.01.2026 - MRNA Stock was down 7.0%

• Despite a positive performance over the past year and year-to-date, Moderna's stock witnessed a bearish movement today. This comes in light of successful partnerships and promising experimental vaccines.
• The robust financial results and pipeline progress of Merck & Co. may have diverted investor attention from Moderna, impacting MRNA's stock adversely.
• Moderna's announcement of an upcoming webinar on decision intelligence for an autonomous cold chain underscores its dedication to innovation. However, this development might not have been sufficient to counter the prevailing market sentiment affecting MRNA's stock.
• The FDA's recent request for monitoring myocarditis in a new COVID antibody trial possibly added to market uncertainty. This factor could have influenced the bearish movement in Moderna's stock observed today.

29.00.2026 - MRNA Stock was up 5.0%

• Moderna's bullish movement could be attributed to positive sentiment surrounding its ongoing developments and potential in the healthcare sector.
• The reduction in stake by Federated Hermes Inc. and director Noubar Afeyan might have initially raised concerns, but the market likely focused more on the broader positive outlook for the company.
• The strong performance of healthcare stocks in the past month, including Moderna, reflects investor confidence in the sector, further boosting MRNA's upward momentum.
• With the focus on NLRP3 inhibitors by other companies like Eli Lilly and BioAge Labs, the overall excitement and advancements in healthcare innovation could have positively influenced Moderna's stock performance.

29.00.2026 - MRNA Stock was up 5.7%

• Moderna's stock soared as investors exhibited confidence in the company's innovative mRNA technology and its promising prospects for growth.
• The decision by Federated Hermes Inc. and director Noubar Afeyan to reduce their stake may have sparked some initial market uncertainty, but the prevailing sentiment leaned towards positivity.
• The stock's remarkable performance could also be linked to its inclusion in the top healthcare stocks list, showcasing its resilience and growth potential in the sector.
• The increased market interest in healthcare stocks, evident from the leading ETFs and the focus on NLRP3 inhibitors by other entities, likely contributed to the further elevation of Moderna's stock price.